DE60014130D1 - Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren - Google Patents
Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitorenInfo
- Publication number
- DE60014130D1 DE60014130D1 DE60014130T DE60014130T DE60014130D1 DE 60014130 D1 DE60014130 D1 DE 60014130D1 DE 60014130 T DE60014130 T DE 60014130T DE 60014130 T DE60014130 T DE 60014130T DE 60014130 D1 DE60014130 D1 DE 60014130D1
- Authority
- DE
- Germany
- Prior art keywords
- diseases
- compounds
- useful
- compounds used
- heterocyclic compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15792299P | 1999-10-06 | 1999-10-06 | |
US157922P | 1999-10-06 | ||
PCT/US2000/027444 WO2001025238A2 (en) | 1999-10-06 | 2000-10-05 | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60014130D1 true DE60014130D1 (de) | 2004-10-28 |
DE60014130T2 DE60014130T2 (de) | 2006-03-09 |
Family
ID=22565906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60014130T Expired - Lifetime DE60014130T2 (de) | 1999-10-06 | 2000-10-05 | Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1222187B1 (de) |
JP (1) | JP5036112B2 (de) |
AT (1) | ATE277044T1 (de) |
CA (1) | CA2384378C (de) |
DE (1) | DE60014130T2 (de) |
ES (1) | ES2225231T3 (de) |
MX (1) | MXPA02003364A (de) |
WO (1) | WO2001025238A2 (de) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002327422A1 (en) | 2001-08-03 | 2003-03-18 | Abbott Laboratories | Method of identifying inhibitors of lck |
EP1448199A1 (de) * | 2001-11-09 | 2004-08-25 | Boehringer Ingelheim Pharmaceuticals Inc. | Benzimidazole zur verwendung als protein-kinase-hemmer |
US7361671B2 (en) * | 2001-11-15 | 2008-04-22 | The Institute For Pharmaceutical Discovery, Inc. | Substituted heteroarylalkanoic acids |
WO2003057690A1 (en) | 2001-12-27 | 2003-07-17 | Theravance, Inc. | Indolinone derivatives useful as protein kinase inhibitors |
CA2494942A1 (en) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzimidazole compounds |
DE10237423A1 (de) * | 2002-08-16 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen |
DE10337942A1 (de) * | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
DE10342503A1 (de) * | 2003-09-12 | 2005-04-14 | Merck Patent Gmbh | Benzyl-Benzimidazolylderivate |
DE10349587A1 (de) * | 2003-10-24 | 2005-05-25 | Merck Patent Gmbh | Benzimidazolylderivate |
WO2005042530A1 (en) * | 2003-10-30 | 2005-05-12 | Boehringer Ingelheim (Canada) Ltd. | Rsv polymerase inhibitors |
EP1768662A2 (de) | 2004-06-24 | 2007-04-04 | Novartis Vaccines and Diagnostics, Inc. | Immunstimulatoren kleiner moleküle und assays für deren nachweis |
WO2006068760A2 (en) | 2004-11-19 | 2006-06-29 | The Regents Of The University Of California | Anti-inflammatory pyrazolopyrimidines |
ZA200707896B (en) | 2005-03-14 | 2009-07-29 | High Point Pharma Llc | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors |
TWI370820B (en) | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
WO2007087068A2 (en) * | 2006-01-13 | 2007-08-02 | Pharmacyclics, Inc. | Inhibitors of tyrosine kinases and uses thereof |
WO2008127226A2 (en) | 2006-04-04 | 2008-10-23 | The Regents Of The University Of California | P13 kinase antagonists |
CN102887900B (zh) | 2006-09-22 | 2015-04-29 | 药品循环公司 | 布鲁顿酪氨酸激酶的抑制剂 |
US8987233B2 (en) | 2006-11-03 | 2015-03-24 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
US20120101114A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
WO2009046448A1 (en) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
KR101897881B1 (ko) | 2008-01-04 | 2018-09-12 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
JP5547099B2 (ja) | 2008-03-14 | 2014-07-09 | インテリカイン, エルエルシー | キナーゼ阻害剤および使用方法 |
US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
CN102124009B (zh) | 2008-07-08 | 2014-07-23 | 因特利凯公司 | 激酶抑制剂及其使用方法 |
EP2307025B1 (de) | 2008-07-16 | 2017-09-20 | Pharmacyclics LLC | Hemmer der bruton-tyrosinkinase zur behandlung fester tumore |
UY32138A (es) * | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
MX2011003239A (es) | 2008-09-26 | 2011-04-28 | Merck Sharp & Dohme | Nuevos derivados de bencimidazol ciclicos utiles como agentes anti-diabeticos. |
JP5731978B2 (ja) | 2008-09-26 | 2015-06-10 | インテリカイン, エルエルシー | 複素環キナーゼ阻害剤 |
US8697709B2 (en) | 2008-10-16 | 2014-04-15 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
JP2012507530A (ja) | 2008-10-29 | 2012-03-29 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病剤である新規な環状ベンズイミダゾール誘導体 |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
UY32470A (es) * | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011146882A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
NZ789041A (en) | 2010-06-03 | 2023-09-29 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
US8759537B2 (en) | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
CA2817577A1 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8674113B2 (en) | 2010-12-10 | 2014-03-18 | Boehringer Ingelheim International Gmbh | Compounds |
US8466186B2 (en) | 2010-12-10 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Compounds |
US8486968B2 (en) | 2010-12-10 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Compounds |
KR101875720B1 (ko) | 2011-01-10 | 2018-07-09 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀린온 및 이의 고체 형태의 제조 방법 |
CN106619647A (zh) | 2011-02-23 | 2017-05-10 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
EA201490265A1 (ru) | 2011-07-13 | 2014-12-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
KR20140063605A (ko) | 2011-07-19 | 2014-05-27 | 인피니티 파마슈티칼스, 인코포레이티드 | 헤테로사이클릭 화합물 및 그의 용도 |
JP6027610B2 (ja) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環式化合物及びその使用 |
AR091790A1 (es) | 2011-08-29 | 2015-03-04 | Infinity Pharmaceuticals Inc | Derivados de isoquinolin-1-ona y sus usos |
MX370814B (es) | 2011-09-02 | 2020-01-08 | Univ California | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
KR20200017549A (ko) | 2012-06-04 | 2020-02-18 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
EP2877598A1 (de) | 2012-07-24 | 2015-06-03 | Pharmacyclics, Inc. | Mutationen im zusammenhang mit der resistenz gegenüber hemmern der bruton-tyrosinkinase (btk) |
EP2900673A4 (de) | 2012-09-26 | 2016-10-19 | Univ California | Ire1-modulation |
MX2015006168A (es) | 2012-11-15 | 2015-08-10 | Pharmacyclics Inc | Compuestos de pirrolopirimidina como inhibidores de quinasas. |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
WO2015017812A1 (en) | 2013-08-02 | 2015-02-05 | Pharmacyclics, Inc. | Methods for the treatment of solid tumors |
ES2709509T3 (es) | 2013-08-12 | 2019-04-16 | Pharmacyclics Llc | Procedimientos para el tratamiento de cáncer amplificado por HER2 |
US9624224B2 (en) | 2013-09-30 | 2017-04-18 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP3052485B1 (de) | 2013-10-04 | 2021-07-28 | Infinity Pharmaceuticals, Inc. | Heterocyclische verbindungen und verwendungen davon |
WO2015061751A1 (en) | 2013-10-25 | 2015-04-30 | Pharmacyclics, Inc. | Methods of treating and preventing graft versus host disease |
EP4066834A1 (de) | 2014-03-19 | 2022-10-05 | Infinity Pharmaceuticals, Inc. | Heterocyclische verbindungen zur verwendung in der behandlung von pi3k-gamma-vermittelten erkrankungen |
WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US9533991B2 (en) | 2014-08-01 | 2017-01-03 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
MX2017001671A (es) | 2014-08-07 | 2017-07-04 | Pharmacyclics Llc | Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton. |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
NZ734446A (en) | 2015-03-03 | 2022-12-23 | Pharmacyclics Llc | Pharmaceutical formulations of bruton’s tyrosine kinase inhibtor |
EP3350183A1 (de) | 2015-09-14 | 2018-07-25 | Infinity Pharmaceuticals, Inc. | Feste formen von isochinolinonderivaten, herstellungsverfahren, zusammensetzungen damit und verwendungsverfahren dafür |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN109640999A (zh) | 2016-06-24 | 2019-04-16 | 无限药品股份有限公司 | 组合疗法 |
CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
US20220229072A1 (en) | 2019-06-04 | 2022-07-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN112409347B (zh) * | 2020-11-05 | 2022-10-14 | 江苏省中国科学院植物研究所 | 吴茱萸乙二胺a及其制备方法和抗肿瘤用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR65025B (en) * | 1977-07-21 | 1980-06-16 | Thomae Gmbh Dr K | Method for the preparation of new imidazo-isokinolin-diones |
DE2732951A1 (de) * | 1977-07-21 | 1979-02-08 | Thomae Gmbh Dr K | Neue imidazo-isochinolin-dione |
EP0322746B1 (de) * | 1987-12-30 | 1996-05-29 | Orion Corporation Limited | Heterocyclische Verbindungen |
US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
AU744281B2 (en) * | 1997-11-10 | 2002-02-21 | Bristol-Myers Squibb Company | Benzothiazole protein tyrosine kinase inhibitors |
-
2000
- 2000-10-05 ES ES00968713T patent/ES2225231T3/es not_active Expired - Lifetime
- 2000-10-05 JP JP2001528182A patent/JP5036112B2/ja not_active Expired - Fee Related
- 2000-10-05 AT AT00968713T patent/ATE277044T1/de active
- 2000-10-05 WO PCT/US2000/027444 patent/WO2001025238A2/en active IP Right Grant
- 2000-10-05 MX MXPA02003364A patent/MXPA02003364A/es active IP Right Grant
- 2000-10-05 DE DE60014130T patent/DE60014130T2/de not_active Expired - Lifetime
- 2000-10-05 EP EP00968713A patent/EP1222187B1/de not_active Expired - Lifetime
- 2000-10-05 CA CA2384378A patent/CA2384378C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2225231T3 (es) | 2005-03-16 |
WO2001025238A2 (en) | 2001-04-12 |
JP5036112B2 (ja) | 2012-09-26 |
WO2001025238A3 (en) | 2001-10-25 |
EP1222187B1 (de) | 2004-09-22 |
EP1222187A2 (de) | 2002-07-17 |
MXPA02003364A (es) | 2002-08-23 |
DE60014130T2 (de) | 2006-03-09 |
CA2384378A1 (en) | 2001-04-12 |
CA2384378C (en) | 2011-05-24 |
JP2003527328A (ja) | 2003-09-16 |
ATE277044T1 (de) | 2004-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60014130D1 (de) | Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren | |
ATE385498T1 (de) | Heterozyklische verbindungen als inhibitoren von tyrosin-kinasen | |
EA200600991A1 (ru) | Производные 3-циклоалкиламинопирролидина в качестве модуляторов рецепторов хемокинов | |
EA199700356A1 (ru) | ПИРИДО[2,3-d]ПИРИМИДИНЫ ДЛЯ ИНГИБИРОВАНИЯ ОПОСРЕДОВАННОЙ ПРОТЕИНТИРОЗИНКИНАЗЫ КЛЕТОЧНОЙ ПРОЛИФЕРАЦИИ | |
ATE190978T1 (de) | 6-aryl-pyrido(2,3-d)pyrimidine und -naphthyridine zur hemmung der durch protein-tyrosin-kinase hervorgerufenen zellvermehrung | |
ATE473980T1 (de) | Triazolopyridazine als proteinkinase-inhibitoren | |
DE602005024274D1 (de) | Als aurora-kinase-inhibitoren nutzbare thienopyrimidine | |
DE60214703D1 (de) | Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen | |
DE69918422D1 (de) | Phthalazinone pde iii/iv hemmer | |
ATE444960T1 (de) | Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer | |
DE60326646D1 (de) | Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen | |
BRPI0414533A (pt) | composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90 | |
ATE454152T1 (de) | 2-aminopyrimidin-derivate als raf-kinase-hemmer | |
EA200001176A1 (ru) | Гетероциклические ингибиторы p38 | |
ATE532781T1 (de) | 5-(acylamino)indazol-derivate als kinase- inhibitoren | |
AU2735201A (en) | Pyrimidine and triazine kinase inhibitors | |
SE0302487D0 (sv) | Novel compounds | |
BRPI0616630B8 (pt) | compostos de pirazol substituídos | |
RU2006129891A (ru) | Производные индолилмалеимида в качестве ингибиторов ркс | |
DE602004012758D1 (de) | Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung | |
BRPI0407841A (pt) | inibidores heterocìclicos de quinase | |
ATE246684T1 (de) | Substituierte 1,4-dihydroindeno(1,2-c)pyrazole als inhibitoren von tyrosinkinase | |
ATE328898T1 (de) | Chemotaxis hemmendes protein von staphylococcus aureus (chips) und dessen verwendung | |
UA100489C2 (en) | Anthranilamide insecticides | |
BR0010488A (pt) | Tienocicloalqu(en)ilamino-1,3,5-triazinas substituìdas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |